Bayhill Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Palo Alto CA United States (2000)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2004
NCT00103974
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Alternative names

Bayhill Therapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

bht-3009 (2 trials)

Drugs in Phase 1 Trials (2)

bht-3021 (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Hypoglycemia (Phase 1)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3